Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Stentys Establishes U.S. Operations In Princeton, N.J.
Medical device pioneer Stentys announced that it has established U.S. operations in Princeton, N.J., where the Company will focus its R&D efforts. The Princeton operation will be the cornerstone of the Company"s efforts when seeking FDA clearance to market its self-expanding and disconnectable stent platform.

Northeast Colorado Conference Discusses HIV/AIDS Needs Assessment Findings
Rural Solutions, an organization in northeast Colorado, held the "Community HIV/AIDS Education and Action Conference" as part of its ongoing effort to address issues related to HIV, the Sterling Journal-Advocate reports. At the conference, the organization presented the results of a recent needs assessment of HIV/AIDS services in the northeastern part of the state - conducted in partnership with the Center for Research Strategies and funded through the Colorado Department of Public Health and Environment - which found that HIV prevention services in the area are limited; barriers exist for HIV testing including confidentiality and costs; and mental health and substance use services for at-risk people also are limited, according to the Journal-Advocate (Jones, Sterling Journal-Advocate, 6/17).
News of the day
ISTA Pharmaceuticals Announces Positive Results For Phase 2 Study Of Low-Dose Bromfenac In Dry Eye Disease
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease (keratoconjuctivitis sicca) using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom(R) (bromfenac ophthalmic solution) 0.09%. The study achieved statistical significance in the primary endpoint of the objective sign of conjunctival staining (Lissamine Green test) as compared to baseline. The study also achieved statistical significance on the objective sign of corneal staining (Fluorescein test) as compared to baseline. Patients also achieved statistically significant improvements in subjective symptoms measured by the Ocular Surface Disease Index (OSDI) and improvement in patients" most bothersome ocular symptoms.
Oncology

What Is The Relationship Between Hepatocellular Carcinoma And Type 2 Diabetes Mellitus?

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths. Type 2 diabetes mellitus has been associated with HCC. However, the relationship between type 2 diabetes mellitus and the underlying liver cirrhosis, and the effects of antidiabetic therapy on HCC risk have not yet been fully evaluated. A research team led by Dr. Valter Donadon from Pordenone Hospital addressed this question. Their study was published in the World Journal of Gastroenterology. Enrolled in this study were 465 HCC patients, 618 cirrhosis patients and 490 control subjects. They evaluated the odds ratio (OR) for HCC by univariate and multivariate analysis. Moreover, OR for HCC in diabetic subjects treated with insulin or sulphanylureas and with metformin were calculated. The prevalence of diabetes mellitus was 31.2% in HCC, 23.3% in cirrhotic patients and 12.7% in the Control group. By univariate and multivariate analysis, the OR for HCC in diabetic patients were respectively 3.12 (95%CI: 2.2-4.4, P World J Gastroenterol 2009; 15(20): 2506-2511 Correspondence to: Dr. Valter Donadon, Department of Medicine, Internal Medicine 3rd, Pordenone Hospital, Via Montereale 24, Pordenone 33170, Italy. Lai-Fu Li World Journal of Gastroenterology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009